Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

PORTLAND, GA, UNITED STATES, November 5, 2024 /EINPresswire / -- The global Implantable Insulin Pump Market was pegged at $2.67 billion in 2020, and is estimated to reach $6.44 billion by 2030, ...

PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

pump manufacturers, regulatory authorities, and policymakers can best ensure the safety of new and long-standing users of insulin pumps as the technology continues to develop. We gathered evidence ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.

Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation ...

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

Bernstein initiated coverage of Insulet (PODD) with an Outperform rating and $300 price target Innovation is driving accelerated insulin pump ...

Opens in a new tab or window A shorter-than-expected battery life prompted a voluntary recall of certain insulin pumps from Medtronic's MiniMed 600 and 700 series, the FDA detailed on Thursday.